Biogen (BIIB) Could Trade Up to ~$350/Share Into FDA Adu Decision - Guggenheim

August 7, 2020 8:45 AM
Guggenheim Securities analyst Yatin Suneja weighed in on Biogen (NASDAQ: BIIB) after the company announced the FDA had granted a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Trader Talk

Next Articles